U.S. market Closed. Opens in 8 hours 19 minutes

AVTE | Aerovate Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 2.6100 - 2.6850
52 Week Range 1.2500 - 32.42
Beta 1.45
Implied Volatility 195.41%
IV Rank 20.40%
Day's Volume 73,885
Average Volume 788,919
Shares Outstanding 28,874,500
Market Cap 76,806,170
Sector Healthcare
Industry Biotechnology
IPO Date 2021-06-30
Valuation
Profitability
Growth
Health
P/E Ratio -0.89
Forward P/E Ratio N/A
EPS -2.99
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 51
Country USA
Website AVTE
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
*Chart delayed
Analyzing fundamentals for AVTE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see AVTE Fundamentals page.

Watching at AVTE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on AVTE Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙